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Condusion: We concluded that cefepime and imipenemfcilastatin were
active against most of the pathogens causing nosocomial pneumonia in
ICU patients and ware clinically equally effective for monotherapy.
[TUfI4N4] Febrile neutropenia-role and evolution of
monotherapy
R. Ramphal
University ofF/orida, Gainesl,ille, Utlited States
Patients with febrile neutropenia have become a significant population in
large and specialized medical centers. They comprise a heterogeneous group
ofpatients that have different prognoses and risks for infection. Solid tumor
and lymphoma patients make up the largest number of this group followed
by leukemia patients, and bone marrow ur stem cell transplantation patients.
The prognosis of all patients with febrile neutropenia has improved
significantly over the past 20 years despite more aggressive therapies for
malignancy. Antibiotics have been the most signifieant improving factor.
Antibacterial therapy has improved in treatment approaches and the avail-
able drugs. Combination therapy with a /3-lactam and an aminoglycoside
has been a standard ofcare since the introduction ofcarbenicillin in the 1970s.
This approach was replaced by more potent antipseudomonal and anti
gram-negative drugs. In some areas, ceftazidime or imipenem monotherapy
became interchangeable with combination therapy. Certain factors are now
driving the evolution of therapy to newer agents, including bacterial
resistance and changes in organisms cultured from infections. However,
the case for continued monotherapy is stronger because of the introduction
of cefepime, fourth-generation cephalosporin. with improved gram-posi-
tive and gram-negative activity over ceftazidime and meropenem, a
carbapenem. The outpatient use of antibiotics is another direction to
manage these patients. Accumulating evidence indicates that patients at
lower risk for infection (eg, those with a shorter anticipated duration of
neutropenia), may be managed as outpatients and oral antibiotics may be
safe. It appears that maximum doses ofantibiotics as used in the past may not
be needed. The role offluoroquinolones in this group of patients has clearly
been established and newer agents may expand their use. The antibiotic
management of febrile neutropenia should include risk determination,
knowledge of prevailing resistance patterns and the epidemiology of
infections in the institution.
ITuI14-SI New alternatives in the empiric treatment of
meningitis and other serious pediatric infections
D. Kafetzis
A.l1laia Children's Hospital, Athens, Greece
Hospital-acquired bacterial infections represent a key cause of substantial
morbidity and mortality among the pediatric population. It is estimated that
almost 10% of hospitalized patients in the United States and Europe will
develop an infection during their hospital stay. The most common nosoco-
nJal infections afflicting pediatric patients are hospital-acquired pneumonia,
urinary tract infections, blood stream infections, and surgical site infections.
Pediatric neutropenic patients are prone to developing bacterial infections.
Treatment is often a challenge and requires initiation of empirical therapy
with a broad-spectrum antibiotic. Bacterial meningitis is another cause of
many pediatric intensive care unit admissions. Cefepime is a fourth-genera-
tion cephalosporin with excellent in vitro and in vivo activity against
pathogens that are commonly implicated in serious pediatric infections.
Cefepime has been shown to be as safe and effective as ceftazidime,
cefotaxime, and cefuroxime in the treatment of lower respiratory tract
infections. There was a clinical response rate in 88% to 100% of patients. In
patients with urinary tract infections, primarily caused by E coli and Proteus
species, cefepime 50 mg/kg/dose every 8-12 hours has been as effective and
safe as ceftazidime exhibiting clinical cure and bacteriologic eradication rates
above 90%. In pediatric patients with febrile neutropenin, cefepime has
shown comparable efficacy rates to ceftazidime. Patients treated with
cefepime developed fewer new infections and required less concomitant
systemic antimicrobial therapy than ceftazidime. In several trials conducted
in Europe and Latin America, patients with bacterial meningitis had similar
cure rates compared to those who were treated with eefotaxime and
ceftriaxone. Eradication rates of the most commonly isolated pathogens,
H influenzae, N meningitidis, and S pneumoniae, were above 90%.
Cefepime has a favorable safety and pharmacokinetic profile allowing for
twice-daily or thrice-daily administration depending on the severity of
infection. It has adequate tissue penetration and excellent activity against
gram-positive and gram-negative pathogens often implicated in serious
pediatric infections. Cefepime is an ideal choice for the empiric treatment of
pediatric patients.
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ITu11S-11 The virosome vaccine principle
JanWilschut
Laboratory ofMolecular Virology, Department ofMedical Microbiology,
University of Gronin.l1en and Academic Hospital, Ant. Deusinglaan 1, 9713 A V
Gronin.l1en, Netherlands
Induction of an effective immune response by vaccination requires a proper
processing and presentation of the vaccine antigen by antigen-presenting
cells (APCs). Virosomes, derived from, e.g., influenza virus, represent a
promising carrier system for delivery of antigens to APCs. Virosomes are
reconstituted viral envelopes which can be generated from native virus
through a detergent solubilization and removal procedure. Antigenic pep-
tides or proteins may be encapsulated in the virosomal lumen by including
them in the reconstitution mixture prior to the detergent removal step.
Antigens may also be coupled to the surface of the virosomes.
Functionally reconstituted virosomes retain the cell entry and membrane
fusion characteristics of the native virus. Thus, influenza-derived virosomes
enter cells, including APCs, through receptor-mediated endocytosis and
subsequent fusion from within acidic endosomes. In this manner, virosome-
encapsulated antigens are released into the cell cytosol and, thus, into the
MHC class I antigen processing pathway. On the other hand, antigens
associated with the virosomal surface are introduced into the endosomal
membrane, facilitating their processing in the MHC class n presentation
pathway.
We have studied the capacity of influenza virosomes to prime class I
MHC-restricted cytotoxic T lymphocyte (CTL) activity in mice against a
peptide or whole-protein antigen. An efficient CTL response was induced
with virosomes containing a synthetic peptide corresponding to a CTL
epitope of the influenza nucleoprotein or containing the protein ovalbumin.
The superior antigen-delivery capaciry ofvirosomes is primarily due to their
membrane fusion activity, since fusion-inactivated antigen-containing viro-
somes lack the ability to efficiently prime CTL activity.
ITul15-21 Influenza vlrosomes to fight Influenza?
J. Oxford
Department of Medical Microbiology. St. Bartholomew's and The Royal
London School ofMedicitle and Dentistry, London, United Kingdom
Influenza vaccine will remain the cornerstone in the clinical management of
influenza alongside new developments in anti NA inhibitors. The current
influenza vaccines prevent hospitalization and mortality in the elderly and 'at
risk' vaccine groups. However, a low proportion ofelderly are non or poor
responders to vaccine. Therefore, new adjuvants are urgently required.
The in vivo ferret model data will be presented which establishes that
influenza virosome formulations have high efficacy in preventing influenza
virus excretion and clinical symptoms. Moreover intranasal administration
of virosome vaccine induces circulatory IgG antibody to influenza. Recent
clinical studies of virosomes in volunteers will also be presented in the above
context.
ITuI1S-3! Clinical experience with an inactivated virosome
fonnulatec:l hepatitis A vaccine
P. Bovier'. L. Loutan'. F. Ambrosch2, R. GliickJ , C. HerzogJ
'Department l.Community Medicine, University Hospital, Geneva,
Switzerland; Institute for Specif,c Prophylaxis & Tropical Medicine,
University of Vienna, Austria; Swiss Serum and Vaccine Institute, Berne,
Switzerland
Ten years of clinical experience with the aluminium-free, virosome for-
mulated. inactivated hepatitis A vaccine (500 RIA units) are summarised.
Data are presented on the dosing regimen (months 0, 12), on safety and
immunogenicity (also in comparison to an aIuminium-ad!lOrbed vaccine),
on potential interactions with other vaccines, on use in children and in
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immune compromised hosts, and on the protective efficacy. A total of 35
studies in 10 countries involving over 6000 subjects, including 500 children
and 480 controls, have been performed. Clinical experience and postmar-
keting surveillance since licensure in 1994, has shown the vaccine to be well
tolerated, rarely causing mild, transient systemic and hardly any local
reactions. Protective antibody titers (> 1=20 mlUIml) are obtained one
month after a 1st dose in 95-100% ofhealthy adult vaccinees. After a single
dose protective antibody levels (incl. neutralising antibodies) develop from
day 9 onward and by day 15 over 90% ofvaccinees are protected. There is no
clinical relevant interference from concomitant use of influenza vaccine,
yellow fever or other travel vaccines or of immunoglobulins. In a double-
blind, placebo-controlled field trial in children under 5 year old in an
endemic area a protective efficacy of> 95% was found. This aluminium-
free, virosome formulated hepatitis A vaccine is very well tolerated, is highly
immunogenic and confers long-lasting (> 20 years) protection against
hepatitis A.
IruM-41 Virosome vaccines: Suitable for several routes of
administration
G. Frosnerl , R. Steffen2, R. Gliick3, C. Herzog3
rMax von Pettenkofer Institute, Munich, Gennany; 2Institute of Social and
Preventive Medidne, University of Zurich; .ISrviss Serum and Vaaine Institute,
Beme. Switzerland
Virosomes, a new type of antigen delivery system. are reconstituted
influenza virus envelopes, composed mainly by a phospholipid bilayer and
intercalated influenza haemagglutinin. In the case of the today only com-
mercialised types ofvirosome vaccines against hepatitis A and influenza egg
yolk lecithin and synthetic cephalin is added to enlarge the surface of the
virosome globule. By the nature of their composition virosomes do not
stimulate inflammatory reactions upon parenteral or mucosal administra-
tion. Unlike alumininium-adsorbed vaccines virosomes can, therefore, be
injected intradermally. With the still fusion-active haemagglutinin mole-
cules on the surface the virosomes, including any attached vaccine antigens,
bind to and are taken up by immuneompetent cells (macrophages) in the
muscle, in the skin and in the mucosa. Clinical data are presented on
intramuscular (i.m.), subcutaneous (s.c.) and intradermal (i.d.) administra-
tion of a virosome formulated hepatitis A vaccine and on the i.m. and
intranasal (i.n.) administration of a virosome formulated subunit influenza
vaccine. The local tolerability is excellent for all four routes. The i.d.
administration of 0.1 ml, which gave protective, although somewhat
lower antibody titers than the full 0.5 ml i.m. dose, will allow a considerable
reduction in immunisation costs. This could be important for the hep:atitis A
endemic developing countries aiming to immunize in the near future large
population groups. The i.n. immunisation against influenza elicites with the
help ofsmall amounts ofheat-labile E. coli toxin as adjuvant strong humoral
and mucosal immune responses, demonstrating the feasibility of mucosal
immunisation with this new type of antigen delivery system.
IND16 - bioMerieux: Are molecular diagnostics possible
for every laboratory?
[TuI16-21Is there any interest in daily testing for molecular
biology? The dinician's point of view
J. -c. Pechere
University ofGeneva, Switzerland
Microbiology testing (MT) is performed for disease management and health
management. Dealing with individual patients, clinicians use MT primarily
to adjust treatments and set preventive measures in case of communicable
diseases such as MRSA or tuberculosis. For both aims, time to results is a big
issue. Molecular technology such as DNA fingerprinting, automated PCR,
hybridisation technologies, and, soon, DNA chips, has allowed to shorten
significantly the time to result in MT. so that results are made available the
day of the sampling. This performance provides clinical benefit, economic
benefit and patient satisfaction. Rapid results were unusual with the con-
ventional techniques, since microscopic exam is rarely fully diagnostic, and
cultures require typically an overnight incubation or more. Modem rapid
techniques are especially efficient with regard to time to result when dealing
with slow growing or fastidious organisms like M. tuberculosis. L. pneumo-
phila. C. trachomatis or viruses. However, rapid testing has to be made
available on a daily basis: if not, the benefit of promptitude in the testing
would be lost. Examples ofcombined economic and clinical values ofrapid
testing include tuberculosis, Chlamydia prevention and control, detectionl
eradication of H. pylori in gastro-duodenal diseases, and safety of blood
supply.
PO - Fluoroquinolones in respiratory tract infections
IWeol Fluoroquinolones in respiratory tract infections - pro
position
Lionel Mandell
McMaster Clinic, Hendt!rson Hospital, Hamilton, Ontario, Canada
Respiratory tract infections arc a frequent came of physician visits and are
among the commonest reasons for antibiotic prescriptions. Lower respira-
tory tract infections such as acute exacerbations of chronic bronchitis,
community-acquired pneumonia and hospital acquired pneumonia are
associated with considerable morbidity and mortality and have a major
impact on society and health care economics. Over the past decade. it has
become apparent that a number ofissues must be considered whcn planning
treatment regimens for patients with such lower respiratory tract infections.
These include: the significance of the disease, the increasing prevalence of
resistant pathogens, the possibility of copathogenicity and the realization
that inappropriate initial therapy in severely ill patients with pneumonia can
result in increased mortality. The fluoroquinolones are an important addi-
tion to our therapeutic armamentarium. Newer agents in particular offer
improved activity against the pneumococcus while retaining activity against
most gram negative pathogens. In addition to their reasonably broad
spectrum of activity they offer the advantage of monotherapy for most
patients. This is associated with compliance and cost benefits. The role for the
quinolones in selected respiratory tract infections is becoming quite clear and
will be discussed during the debate.
Influenza and other respiratory viruses
IMoS2! New antiviral strategies for management of influenza
Frederick G. Hayden
Univt!rsity of Virginia School of Medicine. Charlollesvil/t!. VA, United States
Two classes of anti-influenza agents, M2 ion channel blockers and neur-
aminidase (NA) inhibitors, have documented effectiveness in prevention and
treatment ofinfluenza. Amantadine and rimantadine are orally bioavailable
inhibitors of influenza A virus replication. Therapeutic use speeds recovery
from acute, uncomplicated influenza by 1-2 days ifbegun early in the course
of illness. However, it remains unclear whether treatment is beneficial in
more severe infections or reduces the risk of complications. Rimantadine'ls
associated with a lower risk of CNS adverse effects than amantadine.
Resistance due to single amino acid changes in the M2 protein confers
high level cross-resistance. Rapid emergence of drug-resistant variants
occurs in up to 30% of treated persons, and transmission of these has
caused failures of drug prophylaxis in family contacts and nursing home
residents.
Zanamivir and oseltamivir carboxylate (GS4071) are potent. selective
influenza neuraminidase inhibitors in vitro but have different pharmacoki-
netic properties. Both included zanamivir and the oral prodrug oseltamivir
(GS4104) are therapeutically effective in uncomplicated influenza. Twice
daily inhaled zanamivir treatment shortens symptoms and reduces lower
respiratory tract complications in acute influenza in adolescents and adults.
Twice daily oral oseltamivir is effective in treating acute influenza in adults
and children and also reduces complications leading to antibiotic use.
Treatment efficacy in patients with asthma and COPD is under study.
Both agents are also effective for seasonal or post-exposure prophylaxis of
influenza when used once daily. One instance of resistance emergence to
zanamivir has been recognized in an immunocompromised host, and
GS4071 resistant variants have been recovered very uncommonly « 2%)
from immunocompetent patients. However, these variants show reduced
neuraminidase function and lower replication and pathogenicity than wild-
type virus in animal models. Neuraminidase inhibitors provide significant
advances in the management of influenza A and B virus infections.
